New Pancreatic Cancer Drug Rasonque Gains Approval but Faces Access Challenges

The FDA's approval of Rasonque, a novel drug for pancreatic cancer, was a major milestone for researchers aiming to improve treatment outcomes. However, despite this regulatory success, many patients are experiencing difficulties in obtaining timely access to the medication, raising concerns about distribution and availability.